- Home
- HERZ vs TPST Comparison
HERZ vs TPST Comparison
Compare HERZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | TPST |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 26.2M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | HERZ | TPST |
|---|---|---|
| Price | $17.10 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 32.1K | ★ 94.3K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.62 | $0.95 |
| 52 Week High | $19.30 | $12.22 |
Technical Indicators
Market Signals| Indicator | HERZ | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 26.14 |
| Support Level | $15.61 | N/A |
| Resistance Level | $17.59 | $2.48 |
| Average True Range (ATR) | 0.79 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 57.22 | 13.93 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.